Dr Reddy’s Signals Reset In Europe
Benefits From New Launches And COVID-19
Dr Reddy’s enjoyed a strong showing in Europe in the fiscal fourth quarter amid a string of launches and a ramp-up in France, Italy and Spain, with the Indian firm anticipating continued momentum in the region by leveraging its global portfolio. The firm’s China growth strategy is 'still valid', management maintains.
You may also be interested in...
Dr Reddy’s Sells North American Rights For Celecoxib Oral Solution
India’s Dr Reddy’s has sold the US and Canadian rights to its 25mg/ml Elyxyb (celecoxib) oral solution to US-based BioDelivery Sciences International, for an upfront payment of $6m, followed by $9m within one year from closing the deal.
Teva Sues FDA For Excluding Copaxone From BLA Transition
Teva and US FDA disagree over whether Copaxone is a protein. While generics are already on the market, Teva wants to assert process patents against future would-be competitors, which the firm cannot do through the ANDA pathway.
Dr Reddy’s Debuts Daraprim Rival In US
Dr Reddy’s has launched the first generic version of Daraprim in the US. The company has also introduced naloxone with 180 days of exclusivity under the FDA’s Competitive Generic Therapy pathway, as well as the first US generic of ziprasidone mesylate.